Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for Comprar returned no results
Showing 241 to 255 of 555 results for compare

  1. Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy (TA992)

    Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for HER2-low metastatic or unresectable breast cancer after chemotherapy in adults.

  2. Tebentafusp for treating advanced uveal melanoma (TA1027)

    Evidence-based recommendations on tebentafusp (Kimmtrak) for treating uveal melanoma in adults.

  3. Apremilast for treating moderate to severe plaque psoriasis (TA419)

    Evidence-based recommendations on apremilast (Otezla) for treating moderate to severe plaque psoriasis in adults.

  4. Curos for preventing infections when using needleless connectors (HTG510)

    Evidence-based recommendations on Curos for preventing infections when using needleless connectors.

  5. Single technology appraisal and highly specialised technologies evaluation: User guide for company evidence submission template (PMG24)

    This is the user guide for submission of evidence to the National Institute for Health and Care Excellence (NICE) as part of the single technology appraisal and highly specialised technologies evaluations process. It explains what information NICE requires and the format in which it should be presented

  6. Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension (TA1009)

    Evidence-based recommendations on latanoprost–netarsudil (Roclanda) for previously treated primary open-angle glaucoma or ocular hypertension in adults.

  7. Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma (TA306)

    Evidence-based recommendations on pixantrone (Pixuvri) for treating relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma in adults.

  8. Prevena incision management system for closed surgical incisions (MIB173)

    NICE has developed a medtech innovation briefing (MIB) on Prevena incision management system for closed surgical incisions .

  9. AmnioSense for unexplained vaginal wetness in pregnancy (MIB198)

    NICE has developed a medtech innovation briefing (MIB) on AmnioSense for unexplained vaginal wetness in pregnancy .

  10. Alcohol-use disorders: prevention (PH24)

    This guideline covers alcohol problems among people over 10. It aims to prevent and identify such problems as early as possible using a mix of policy and practice.

  11. Older people with social care needs and multiple long-term conditions (NG22)

    This guideline covers planning and delivering social care and support for older people who have multiple long-term conditions. It promotes an integrated and person-centred approach to delivering effective health and social care services.

  12. Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer (TA668)

    Evidence-based recommendations on encorafenib (Braftovi) plus cetuximab (Erbitux) for treating BRAF V600E mutation-positive metastatic colorectal cancer in adults who have had previous systemic treatment.

  13. PleuraFlow Active Clearance Technology for maintaining chest tube patency (MIB125)

    NICE has developed a medtech innovation briefing (MIB) on PleuraFlow Active Clearance Technology for maintaining chest tube patency .

  14. d-Nav insulin management app for type 2 diabetes (MIB285)

    NICE has developed a medtech innovation briefing (MIB) on d-Nav insulin management app for type 2 diabetes .

  15. Avelumab for treating metastatic Merkel cell carcinoma (TA517)

    Evidence-based recommendations on avelumab (Bavencio) for metastatic Merkel cell carcinoma in adults.